KNSA catalyst calendar

Kiniksa Pharmaceuticals International, plc

Upcoming catalysts
3
Cash runway
Cash generating
Cash & investments
$468M
Phase 3 programs
2

Kiniksa Pharmaceuticals International, plc is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on December 27, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.

Kiniksa Pharmaceuticals International, plc generates cash from operations, so a burn-based runway figure does not apply.

Upcoming catalysts

DateEventTypePhase
December 27, 2026 est. Next quarterly earnings (projected) Earnings —
December 31, 2027 Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387 Trial Milestone Phase 2/Phase 3
December 31, 2027 Transition to KPL-387 Monotherapy Dosing & Administration Study Trial Milestone Phase 2

Track KNSA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open KNSA in the tracker

Recent history

DateEventTypePhase
July 28, 2026 Quarterly results filed (8-K) Earnings —
May 26, 2026 8-K filed: Material agreement Corporate —
May 1, 2026 8-K filed: Leadership change Corporate —
April 28, 2026 Quarterly results filed (8-K) Earnings —
February 24, 2026 Quarterly results filed (8-K) Earnings —
January 14, 2026 8-K filed: Leadership change Corporate —
January 12, 2026 Quarterly results filed (8-K) Earnings —
October 28, 2025 Quarterly results filed (8-K) Earnings —
September 3, 2025 8-K filed: Reg FD disclosure Filing —
July 29, 2025 Quarterly results filed (8-K) Earnings —
June 5, 2025 8-K filed: Reg FD disclosure Filing —
April 29, 2025 Quarterly results filed (8-K) Earnings —
April 23, 2025 8-K filed: Leadership change Corporate —
March 6, 2025 A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease Trial Milestone Phase 2
November 12, 2021 Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation Trial Milestone Phase 2/Phase 3

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.